

Trellus Health plc
("Trellus Health" or the "Company")

Appointment of Administrators
&
Resignation of Nominated Adviser

Further to the notification of 21 August 2026, the Board of Trellus Health has today appointed Paul Zalkin and Tom Parish of Quantum Advisory Ltd as joint administrators of the Company (the "Joint Administrators").

The Joint Administrators will continue previously notified efforts to seek a buyer for certain of the Company's assets including the shares in its operating subsidiary Trellus Health, Inc. No returns are expected to be paid to the Company's shareholders following any such sale.

Resignation of Nominated Adviser and Broker

Singer Capital Markets resigned as the Company's Nominated Adviser and Broker with immediate effect on the appointment of the Joint Administrators. Pursuant to AIM Rule 1, if a replacement Nominated Adviser is not appointed within six weeks, then admission of the Company's ordinary shares will be cancelled on AIM. The Company has no current intention of appointing a replacement Nominated Adviser.

Suspension of Trading on AIM

The Company's ordinary shares remain suspended pending further notice. With the Company's stated intention not to appoint another Nominated Advisor, trading in the Company's ordinary shares will be cancelled on AIM within six weeks of Singer Capital Markets' resignation, which cancellation currently expected to occur on 5 October 2026.

Enquiries:

Trellus Health plc

<https://trellushealth.com/>

Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder
Joy Bessenger, Chief Financial Officer

Via Walbrook PR

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPPPUCWRUPQGPGC